Second quarter (April-
** Other operating income amounted to KSEK 1,731 (2,782)
** Operating loss was KSEK -9,514 (-7,292)
** Loss for the period totaled KSEK -9,604 (-7,976)
** Cash flow from operating activities was KSEK -6,135 (-9,003)
** Loss per share before dilution was
Period (January-
** Other operating income amounted to KSEK 3,409 (4,195)
** Operating loss was KSEK -20,164 (- 13,925)
** Loss for the period totaled KSEK -20,135 (-14,197)
** Cash flow from operating activities was KSEK -16,087 (-10,788)
** Loss per share before dilution was
Significant events in the second quarter
** Preparations for the application to start clinical trials made good progress.
** Documentation and qualification of the production process by
** The COVID-19 pandemic affected work at the
Significant events during the period
**
** A Corporate Governance section was added to the Annual Report, and
** An additional payment of MSEK 3 was received from the EU's Horizon 2020 program
Significant events after the end of the period
** The European Patent Office (EPO) announced that a European patent will be granted to protect the company's tolerogenic cell therapy.
** No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
The information was submitted for publication, through the agency of the contact persons set out above, on
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
https://news.cision.com/idogen/r/idogen-publishes-interim-report-for-1-january---30-june-2021,c3401973
https://mb.cision.com/Main/12368/3401973/1458018.pdf
https://mb.cision.com/Public/12368/3401973/b7263e497834d70d.pdf
(c) 2021 Cision. All rights reserved., source